The Cochrane findings exist within a broader harm reduction framework that public health agencies have been navigating for over a decade:
| Organization | Position on Vaping for Cessation | Key Nuance |
|---|---|---|
| Cochrane (2026) | High-certainty evidence: nicotine vapes outperform NRT | Based on RCT evidence; does not address population-level effects |
| UK NHS / PHE | Endorses vaping as a cessation tool; "at least 95% less harmful than smoking" | Actively prescribes e-cigarettes through stop-smoking services |
| US FDA | Cautiously approves specific PMTA-authorized products; does not broadly endorse vaping | Has authorized 48 products across 5 brands; enforcement gap for unauthorized products |
| CDC | Acknowledges vaping may benefit adult smokers; warns about youth use and dual use | Emphasizes complete cessation as the goal, not long-term vaping |
| American Lung Association | Opposes broad flavor authorizations; urges FDA caution | Concerned about youth uptake and long-term unknowns |
Important context: The US regulatory landscape differs from the UK. The UK actively supports vaping for smoking cessation through NHS stop-smoking services. The US FDA has authorized only 48 specific products through the PMTA process and maintains a different regulatory posture. For US consumers, checking the FDA's authorized product list before purchasing is recommended. For more on how the enforcement gap affects consumers, see our coverage of unauthorized Vuse Pro fruit vapes on store shelves.
